News
France 24 on MSN2h
The big business behind weight-loss drugs: Global market to hit $150 billion by 2035They burst onto the scene four years ago and are taking over the pharmaceutical world. New GLP-1-based drugs like Ozempic, ...
5h
ScienceAlert on MSNNew Weight-Loss Drugs Under Scrutiny Amid Pancreas ConcernsPopular weight-loss drugs like Ozempic and Zepbound have revolutionized how we tackle obesity. But now, emerging reports ...
Some less expensive versions of popular weight loss drugs are no longer available to patients, after the Food & Drug ...
Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...
This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...
Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...
Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.
CVS Caremark will stop covering Eli Lilly's Zepbound, a weight loss drug, due to insurance company changes. Patients are outraged and concerned.
Glucagon-like peptide-1 (GLP-1) injections such as Wegovy (semaglutide) and Zepbound (tirzepatide) are the most effective weight-loss medications available today. Oral GLP-1 pills, such as ...
A separate Prime analysis, however, of year-over-year claims data for Wegovy and Zepbound only found an improvement in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results